A Study of Calderasib (MK-1084) With Midazolam and Digoxin in Healthy Participants (MK-1084-009)
The goal of the study is to see what happens to levels of midazolam and digoxin in a person's body over time (a pharmacokinetic or PK study). Researchers will compare what happens to midazolam and digoxin in the body when it is given with and without another medicine called calderasib. Researchers are testing if digoxin and midazolam levels in the body are different when digoxin and midazolam are given with or without calderasib.
Checked against the public recordLast updated Feb 11, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Merck Sharp & Dohme LLC
- Interventions being studied
- Drug: Calderasib; Drug: Midazolam; Drug: Digoxin
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: The key inclusion criteria include but are not limited to the following: * Is medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vitals signs, and electrocardiograms (ECGs) * Has a body mass index (BMI) ≥18 and ≤32 kg/m\^2, inclusive Exclusion Criteria: The key exclusion criteria include but are not limited to the following: * Has a medical history that may confound the results of the study or poses an additional risk to the participant in the study * Has a history or presence of hypersensitivity or idiosyncratic reaction to the study drugs or related compounds
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Celerion ( Site 0001)Tempe, Arizona
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Feb 11, 2026. Always confirm current availability with the study team.